Overview

Our History

Leadership Team

Partner

Portfolio Advisory Board

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Investor Relations

> Investor Relations

> Announcements and Circulars

Investor Center

Corporate Governance

Financial Report

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Announcements and Circulars

Apr 16, 2026

PROPOSED ADOPTION OF THE FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

Apr 09, 2026

MONTHLY RETURN

Mar 26, 2026

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

Mar 26, 2026

CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

Mar 23, 2026

CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Mar 16, 2026

DATE OF BOARD MEETING

Mar 05, 2026

MONTHLY RETURN

Mar 03, 2026

INSIDE INFORMATION - BUSINESS UPDATE IN RELATION TO APPROVAL OF DORZAGLIATIN FOR MARKETING IN HONG KONG SAR, CHINA

VOLUNTARY ANNOUNCEMENT

Dec 04, 2025

MONTHLY RETURN

About Us

Overview

Our History

Leadership Team

Portfolio Advisory Board

Partner

Media center

Research & Development

Inovation

Dorzagliatin

mGluR5

Presentations

Peer Reviewed Publications

Media

Company News

Media Releases

Video

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Careers

Culture

Join Us

Products&Pipeline

Pipeline

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.